Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00949182|
Recruitment Status : Completed
First Posted : July 30, 2009
Last Update Posted : January 14, 2014
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking blood flow to the tumor. Giving sorafenib tosylate before and after chemoembolization may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving sorafenib tosylate before and after hepatic arterial chemoembolization with doxorubicin hydrochloride and mitomycin C works in treating patients with localized liver cancer that cannot be removed by surgery.
|Condition or disease||Intervention/treatment||Phase|
|Liver Cancer||Drug: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C Other: laboratory biomarker analysis||Phase 2|
- To evaluate the safety and tolerability of sorafenib tosylate therapy when administered before and after doxorubicin hydrochloride-based hepatic arterial chemoembolization (HACE) as assessed by NCI CTCAE v3.0 in patients with localized unresectable hepatocellular carcinoma.
- To determine if sorafenib tosylate decreases the number of HACE treatments required to achieve radiologic tumor kill.
- To assess improvement in progression-free survival.
- To assess changes in monthly AFP levels in patients with AFP-producing tumors.
- To measure VEGF levels.
OUTLINE: Patients receive oral sorafenib tosylate twice daily on days 1-14. Beginning ≥ 3 days later, patients undergo hepatic arterial chemoembolization (HACE)* with doxorubicin hydrochloride and mitomycin C. Beginning ≥ 3 days after the completion of HACE and/or once liver function returns to baseline, patients resume sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients may undergo more than one HACE treatment.
Blood samples are collected periodically for further laboratory analysis.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Micro and Macro Arteriolar Blockade of Hepatocellular Carcinoma (HCC): Treatment With Sorafenib Before and After Hepatic Arterial Embolization (HAE) Therapy for Liver Cancer.|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||June 2013|
Experimental: Sorafenib Tosylate, Doxorubicin, Mytomicin C
Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
Drug: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C
After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
Other Name: Doxorubicin brand name Adriamycin.
Other: laboratory biomarker analysis
- Safety and tolerability as assessed by NCI CTCAE v3.0 [ Time Frame: 06/2009 to 12/2010 ]
- Number of hepatic arterial chemoembolization (HACE) treatments required to achieve objective complete response [ Time Frame: 06/2009 to 12/2010 ]
- Progression-free survival and time to radiologic progression as assessed by CT scan [ Time Frame: 06/2009 to 12/2010 ]
- Overall survival at 6, 12, and 24 months [ Time Frame: 06/2009 to 12/2011 ]
- AFP and VEGF serum levels as assessed at baseline, prior to each HACE treatment, and then every 3 months thereafter [ Time Frame: 06/2009 to 12/2011 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00949182
|United States, New Jersey|
|Rutgers University Hospital|
|Newark, New Jersey, United States, 07101|
|Principal Investigator:||Andrew N. de la Torre, MD||Rutgers University Hospital / St Joseph Medical Center|